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Abstract
Background: Meconium aspiration syndrome (MAS) is a se-
vere lung condition affecting newborns and it can lead to a 
systemic inflammatory response. We previously document-
ed complement activation and cytokine release in a piglet 
MAS model. Additionally, we showed ex vivo that meconi-
um-induced inflammation was dependent on complement 
and Toll-like receptors. Objectives: To assess the efficacy of 
the combined inhibition of complement (C5) and CD14 on 
systemic inflammation induced in a forceful piglet MAS 
model. Methods: Thirty piglets were randomly allocated to 
a treatment group receiving the C5-inhibitor SOBI002 and 
anti-CD14 (n = 15) and a nontreated control group (n = 15). 
MAS was induced by intratracheal meconium instillation, 
and the piglets were observed for 5 h. Complement, cyto-
kines, and myeloperoxidase (MPO) were measured by ELISA. 
Results: SOBI002 ablated C5 activity and the formation of 
the terminal complement complex in vivo. The combined 
inhibition attenuated the inflammasome cytokines IL-1β 
and IL-6 by 60 (p = 0.029) and 44% (p = 0.01), respectively, 
and also MPO activity in the bronchoalveolar fluid by 42% 
(p = 0.017). Ex vivo experiments in human blood revealed 
that the combined regimen attenuated meconium-induced 
MPO release by 64% (p = 0.008), but there was only a negli-
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gible effect with single inhibition, indicating a synergic 
cross-talk between the key molecules C5 and CD14. Conclu-
sion: Combined inhibition of C5 and CD14 attenuates meco-
nium-induced inflammation in vivo and this could become 
a future therapeutic regimen for MAS.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Meconium aspiration syndrome (MAS) is a lung con-
dition that affects newborn infants that inhale meconium 
prior to or during birth [1]. The pathophysiology is com-
plex, involving a mechanical blockade of the airways, ep-
ithelial injury, pulmonary hypertension, surfactant inac-
tivation, and inflammation. MAS reflects a severity spec-
trum that requires lung-supportive treatment ranging 
from oxygen delivery, the administration of surfactant, 
mechanical ventilation, and extra corporeal membrane 
oxygenation in critical cases [2]. Although the incidence 
of severe MAS is low, it is associated with high mortality 
(20–30%) in low-income countries [3]. 
Meconium is a complex mixture of water, epithelial 
cells, bile, mucus and amniotic fluid, containing numer-
ous substances and danger motifs that may induce inflam-
mation [4]. Experimental studies have revealed that me-
conium induces a potent local inflammation in the lungs, 
with the features: leukocyte infiltration, alveolar macro-
phage activation, the release of myeloperoxidase (MPO), 
increased cytokine formation, and apoptosis [5]. Addi-
tionally, MAS-induced complement activation and cyto-
kine release has been shown experimentally in piglets [6], 
and the systemic inflammatory response has been shown 
to correlate with the severity of MAS among neonates [7].
Two important recognition systems of innate immu-
nity, the complement and the Toll-like receptor (TLR) 
systems, appear to play an important role in meconium-
induced inflammation. The degree of complement acti-
vation has previously been shown to reflect the severity of 
MAS [8]. In whole blood, meconium-induced inflamma-
tion is differentially attenuated by inhibition of either the 
complement or the accessory TLR molecule, CD14, but is 
abolished by their combined inhibition [9, 10]. Although 
complement and TLRs act independently, they are con-
nected through mutual interaction and extensive cross-
talk, so a combined blockage of these branches represents 
a potential pronounced anti-inflammatory action on 
downstream inflammatory responses [9, 11]. 
The aim of this study was to examine the effect of a 
combined inhibition of complement (C5) and TLR 
(CD14) in a piglet model of MAS. We hypothesized that 
this regimen would dampen the local and systemic in-
flammatory response evoked by meconium [1].
Materials and Methods
Meconium and Interventional Drugs
Meconium was prepared according to a previously described 
method [12], reconstituted to 99 mg/mL using PBS, and confirmed 
endotoxin-free. Complement inhibition was obtained by using the 
Affibody SOBI002, provided by Swedish Orphan Biovitrum, 
(Stockholm, Sweden). SOBI002 (molecular weight 12 kDa) con-
sists of 2 protein domains, an Affibody ligand, targeting and pre-
venting the cleavage of C5, which is fused to an albumin-binding 
domain that extends its half-life by binding plasma albumin [13]. 
Inhibition of CD14 was obtained by using a recombinant anti-
porcine CD14 IgG2/4 monoclonal antibody (clone rMIL2), and a 
recombinant anti-human CD14 IgG2/4 (clone r18D11), previous-
ly described in detail [14].
Animals, Anesthesia, Exclusion Criteria, Surgery, and 
Monitoring
Norwegian Landrace piglets (Sus scrofa domesticus) of either 
sex, 2 days old at the most, with a mean weight of 2 kg (range 1.8–
2.3 kg) were used. Housekeeping, anesthesia, surgery, euthanasia, 
and recording of hemodynamics and respiratory parameters were 
performed according to previously described procedures [15].
Bronchoalveolavar Lavage
The amount of saline used in the bronchoalveolavar lavage 
(BAL) procedure was tested in pilot experiments. Saline was in-
serted intratracheally followed by 10 s of manual ventilation, be-
fore BAL fluid (BALF) was obtained through suction and stored at 
–70  ° C. A volume of 5 mL of saline occasionally provided an insuf-
ficient sample amount, whereas 10 mL of saline was sufficient 
without affecting the lung function. Ten minutes after the BAL 
procedure with 10 mL of saline, the oxygen saturation, compliance 
and ventilation index were all at level similar to before the proce-
dure. So 10 mL of saline was used in the study. 
Experimental in vivo Model of MAS 
Thirty piglets were randomly allocated into 2 groups, to which 
the investigators were blinded: a treatment group (n = 15) and a 
control group (n = 15). In addition, 5 sham animals were included 
(Fig. 1a). After surgery and stabilization, the BALF was sampled. 
The intervention was provided intravenously prior to meconium 
instillation; anti-CD14 as a bolus of 5 mg/kg, but SOBI002 as a bo-
lus of 5 mg/kg and then as a continuous infusion of 2.5 mg/kg/h 
for the 5-h observational period. As a supplement to systemic in-
tervention, anti-CD14 and SOBI002 were additionally provided 
locally in the lungs, (diluted with PBS to a final concentration of 
300 and 150 µg/mL, respectively) and mixed with the meconium 
solution when this was installed intratracheally in the treatment 
group. An equivalent amount of saline replaced the interventional 
drugs in both the control and sham groups. Hypoxia, mimicking 
perinatal asphyxia, was induced with 8% oxygen in nitrogen (AGA, 
Oslo, Norway) for 10 min and performed just before meconium 
instillation. Meconium (5.5 mL/kg) was administered intratrache-
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ally in 4 boluses within 4 min. The piglets were manually venti-
lated with 100% oxygen in between the boluses. Continuous re-
oxygenation by mechanical ventilation (Baby log 8000+; Drager-
weck, Lübeck, Germany) to preserve an oxygen saturation of 
> 85%, a pCO2 of < 8 kPa limited by an upper peak inspiratory pres-
sure of 40 cm H2O, a positive end expiratory pressure of 5 cm H2O, 
and a maximum respiratory frequency rate of 40/min, according 
to a previously described procedure [12]. Blood samples were tak-
en at regular time points, directly centrifuged, and put on ice be-
fore both EDTA-plasma and serum were stored at –70  ° C. BAL was 
again performed at the time of death (Fig. 1b). 
Experiments ex vivo of Meconium in Human Whole Blood
The ex vivo human whole-blood model has previously been 
described in detail [16]. Briefly, fresh human whole blood was col-
lected from healthy donors in vacutainer tubes anticoagulated with 
the specific thrombin inhibitor lepirudin (Refludan, Pharmion, 
Copenhagen, Denmark). Whole blood was preincubated with the 
inhibitors SOBI002 at 300 µg/mL and/or anti-human CD14 IgG2/4 
(r18D11) at 15 µg/mL and/or PBS for 5 min at 37  ° C. Meconium 
(1 mg/mL) was then added and incubated for 30 min at 37   ° C. 
Phorbol 12-myristate 13-acetate (100 ng/mL; Sigma-Aldrich, 
Darmstadt, Germany) was used as positive control. At the end of 
incubation, EDTA (20 mM) was added to prevent additional com-
plement activation, and the tubes were centrifuged for 15 min at 
1,400 g at 4  ° C. Plasma was isolated and stored at –70  ° C until ana-
lyzed. 
Enzyme Immunoassays 
The C5 inhibitory effect of SOBI002 was tested by using heat-
aggregated immunoglobulin G (IgG) known to be a strong activa-
tor of the classical complement pathway [17]. Serum was added to 
microtiter plates coated with heat-aggregated IgG, and comple-
ment activation was measured as the formation of soluble (s)C5b-
9. The sC5b-9 terminal complement complex was measured in an 
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Fig. 1. Experimental design. a Thirty piglets were randomly allo-
cated to a treatment group (n = 15) that received the complement 
(C5) inhibitor SOBI002 and anti-CD14 and a control group (n = 
15). Five animals were additionally included in a sham group. 
b Schematic illustration of the experimental setup. After surgery 
and stabilization, the intervention with anti-CD14 and SOBI002 
was given as an intravenous (IV) bolus. SOBI002 was also given as 
a continuous infusion throughout the observational period. Hy-
poxia, mimicking perinatal asphyxia, lasted 10 min before meco-
nium was installed in 4 separate boluses over 4 min. As an additive 
to systemic intervention, SOBI002 and anti-CD14 were adminis-
tered intratracheally, together with the instillation of meconium, 
reaching all meconium-affected regions of the lungs. An equiva-
lent amount of saline replaced the interventional drugs in the con-
trol  and sham groups. Bronchoalveolavar lavage (BAL) was per-
formed before baseline and the end of the experiment. 
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cytokines TNF, IL-6, IL-1β, and IL-8 were analyzed by quantita-
tive porcine immunoassay kits from R&D Systems (Minneapolis, 
MN, USA). MPO activity in the porcine plasma was measured us-
ing the species independent MPO activity assay kit (Fluorometric, 
ab 11749; Abcam, Cambridge, UK). The MPO level in human 
plasma was quantified in the human-specific ELISA MPO kit HK 
324 (Hycult Biotech, Uden, The Netherlands), and expressed in 
ng/mL. 
Histopathology 
Lung necropsy specimens were collected from the piglets after 
euthanasia. Slices of lung tissue were fixed in 10% buffered form-
aldehyde and embedded in paraffin. Sections (2- to 4-μm-thick) 
were stained with hematoxylin and eosin, periodic acid Schiff, 
Martius scarlet blue, and phosphotungstic acid-hematoxylin 
stains, and then studied under a Nikon Eclipse 50i light micro-
scope. Photomicrographs were captured with a Nikon DS-U1 dig-
ital camera.
Statistics
GraphPad Prism v7 (San Diego, CA, USA) was used for the 
statistical analysis. The data were analyzed by an area under the 
curve (AUC) test and an unpaired t test with equal standard de-
viation. A p value < 0.05 was considered statistically significant.
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Fig. 2. Lung function and histopathology. Pulmonary function 
measured as pO2/FiO2 ratio (a) indicating hypoxemia, and venti- 
lation index (b) reflecting the magnitude of ventilation support 
were measured at baseline, before instillation of meconium, and 
throughout the experiment. Lung necropsy specimens were col-
lected after euthanasia, processed, and stained. One lung biopsy 
from a representative meconium treated animal (c) and 1 from a 
sham animal (d) are displayed. HE. c Alveolar infiltration with 
neutrophils, increased occurrence of alveolar macrophages, alveo-
lar capillary congestion, and intra-alveolar edema were evident in 
meconium-exposed lung tissue. d No evident lesions except from 
varying signs of alveolar capillary congestion were observed in 
sham lung tissue. Data are presented as mean ± SEM. B, baseline.
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Ethics
The animals were treated in accordance with the Norwegian 
laboratory animal regulations, by researchers certified by the Fed-
eration of European Laboratory Animals Science Association, and 
the study was approved by the Norwegian Animal Research Au-
thority. Informed written consent was obtained from each human 
whole blood donor.
Results
Lung Function and Histopathology in MAS in vivo
Intratracheal meconium instillation induced severe 
lung injury to all animals included in the control and 
treatment group. Severe hypoxia, measured by a steep 
decrease in PaO2/FiO2-ratio which persisted throughout 
the study (Fig. 2a), and ventilation index increased simi-
larly, indicating stiff lungs (Fig. 2b). Meconium-exposed 
lung tissues, irrespective of the intervention, were heavi-
er, firmer, and darker red than the saline-exposed lung 
tissues, and sank instead of floating when immersed in 
the formalin solution. Histological examination revealed 
a massive alveolar infiltration by neutrophils, an in-
creased occurrence of alveolar macrophages, alveolar 
capillary congestion, intra-alveolar edema, and occa-
sional alveolar hyaline membranes in the meconium-ex-
posed lung tissue (Fig. 2c). No evident lesions except for 
varying signs of alveolar capillary congestion were pres-
ent among the sham animals that did not receive any 
meconium (Fig. 2d). 
The Complement Inhibitory Efficacy of SOBI002 in vivo 
To ensure complete C5-cleavage inhibition after 
SOBI002 administration, complement activity was mea-
sured in serum from animals included in the study. Heat-
aggregated IgG-coated plates were used to activate com-
plement, and the degree of activation was related as per-
cent activity relative to complement activity in a pool of 
adult pig serum. SOBI002 completely ablated the genera-
tion of sC5b-9 immediately after administration and re-
mained effective throughout the experiment (Fig. 3a). The 
mean complement activity, including all piglets at base-
line, was 82% (SD 22%) versus the activity obtained in 
adult pig serum (p = 0.17). The formation of sC5b-9 was 
also measured in plasma from all animals at baseline and 
throughout the experiment. In the control group, sC5b-9 
increased considerably from time 0 to 90 min, and re-
mained at the same high level thereafter. In the treatment 
group, SOBI002 attenuated the formation of sC5b-9 com-
pletely during the whole observational period, compara-
ble to the low level observed in the sham animals (Fig. 3b).
Systemic Inflammation Reflected by Plasma IL-1β and 
IL-6
Intratracheal instillation of meconium induced a sys-
temic inflammatory response measured as the increased 
plasma formation of both IL-1β (Fig.  4a) and IL-6 
(Fig. 4b). The combined inhibition of C5 and CD14 at-
tenuated the formation of IL-1β by 60% (p = 0.03) (Fig. 4c) 







































Fig. 3. The complement inhibitory efficacy 
of SOBI002. Complement activity was 
measured in serum in all animals at base-
line, at time 0, and at 240 and 300 min. 
a Heat-aggregated IgG-coated plates were 
used to activate complement, and the de-
gree of complement activity was related as 
percent activity relative to complement ac-
tivation obtained in a pool of adult pig se-
rum. b Systemic complement activation 
measured as soluble (s)C5b-9, was evalu-
ated in all animals from baseline and 
throughout the experiment. Data are pre-
sented as mean ± SEM. B, baseline; CAU, 
complement arbitrary units.
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sus the nontreated control group. TNF did not increase 
after the instillation of meconium whereas IL-8 increased 
moderately in both groups, but an extensive interindi-
vidual measure variation precluded statistical interpreta-
tion (data not shown). 
MPO Activity in BALF
The levels of MPO activity measured in the BALF at 
baseline were similar in all animal groups (Fig. 5a). At the 
end of the experiment, the treatment group receiving the 
combined inhibition of C5 and CD14 had a 42% reduc-
tion of MPO activity versus the nontreated control group 
(p = 0.017). Notably, at the end of the experiment, the 
sham animals had similar MPO activity to that of the 
treatment group. 
Examination of MPO Release ex vivo
The release of MPO into the BALF prompted us to in-
vestigate the role of C5 and CD14 in our standard whole-
blood model where we previously showed the pronounced 
effect on cytokine release ex vivo by inhibiting these mol-
ecules [9]. Meconium incubated in human whole blood 
induced a substantial increase in MPO release within 30 
min of incubation (Fig. 5b). Single inhibition with either 
SOBI002 or anti-CD14 hardly changed meconium-in-
duced MPO release. However, combined inhibition of C5 
and CD14 markedly attenuated MPO release by 64% (p = 
0.008), reaching levels lower than the spontaneous back-
ground activity observed during incubation, indicating 
that a substantial synergistic effect was obtained with the 
combined regimen (Fig. 5b).
Discussion
This study demonstrates, for the first time, that com-
bined inhibition of C5 and CD14 attenuates the systemic 























































Fig. 4. Systemic inflammation, IL-1β, and 
IL-6. Plasma concentrations of IL-1β (a) 
and IL-6 (b) were measured at all time 
points. Statistical comparisons, measured 
as differences in AUC for IL-1β (c) and 
IL-6 (d), were performed between animals 
receiving combined inhibition of C5 and 
CD14 versus the nontreated control group. 
Data are presented as means ± SEM and as 
mean ± 95% CI. B, baseline. * p < 0.05.
Thomas et al.Neonatology 2018;113:322–330328
DOI: 10.1159/000486542
MAS in piglets. In particular, the inflammasome-related 
IL-1β cytokine was substantially inhibited. Additionally, 
MPO activity in the lungs was significantly attenuated by 
the combined regimen, indicating attenuated neutrophil-
mediated tissue injury. The combined regimen’s effect on 
meconium-induced MPO release in human whole blood 
clearly revealed a pronounced and synergistic attenuating 
effect, with a negligible effect being obtained by the single 
inhibition of either C5 or CD14.
In this study, meconium instillation caused an exces-
sive local inflammatory reaction, evidenced by the copi-
ous infiltration of neutrophils, the degradation of tissue 
architecture, and the induced wet and stiff lungs. Meco-
nium is a potent activator of neutrophils and alveolar 
macrophages known to promote fatal lung injury by the 
liberation of inflammatory mediators and oxygen radi-
cals [19]. Thus, it is reasonable to suggest that the profuse 
local inflammatory reaction was the primary cause of the 
observed systemic inflammatory response with increased 
formation of sC5b-9, IL-1β, and IL-6. This is in agree-
ment with observations in neonatal patients [20].
The inhibitory effect of the combined regimen on IL-
1β might be of inflammatory relevance as systemic IL-1β 
formation is activated by caspase-1 in the inflammasome, 
triggering numerous inflammatory responses [21]. Com-
plement activation has been linked to inflammasome ac-
tivation, and the combination of C5a and TNF has been 
demonstrated to be an effective primer of the NLRP3 in-
flammasome [22].
IL-6, a pleiotropic proinflammatory cytokine was ef-
ficiently attenuated by the combined inhibition of C5 and 
CD14. CD14 is a promiscuous upstream molecule impli-
cated in numerous downstream inflammatory effects. 
Previous reports of bacteria- and meconium-induced in-
flammation clearly demonstrate that IL-6 is highly CD14-
dependent whereas IL-1β has been shown to be both 
CD14- and complement-dependent [10, 23]. Although 




































































Fig. 5. Myeloperoxidase in bronchoalveolar lavage fluid and in ex 
vivo human whole blood experiments. MPO-activity was mea-
sured in bronchoalveolar lavage fluid at baseline and at the end of 
the experiment in all animals. a Activity is expressed as relative 
fluorescence units (RFU) referred to an internal standard provided 
with the assay. Statistical analysis was performed to compare the 
treatment with the control group at the end of the experiment, at 
300 min. b Meconium-induced inflammation in human whole 
blood was explored ex vivo, and the inhibitory effect of C5, CD14 
and the combination thereof were evaluated. Data are presented as 
mean ± SEM. Statistical comparisons were performed between 
meconium-incubated whole blood and background at 30 min 
(T30), and between meconium-incubated whole blood and the ef-
fect of the combined inhibition of C5 and CD14. * p < 0.05.
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mutually connected by considerable cross-talk, implying 
that a combined inhibition of the pathways inherit a pro-
nounced anti-inflammatory potential for exogenously as 
well as endogenously induced inflammation [11]. The 
complement inhibitor used in this study, SOBI002, effi-
ciently and completely prevented systemic sC5b-9 forma-
tion, and thus also the formation of the potent anaphyla-
toxin C5a. Interestingly, the complement activity mea-
sured in the piglets in this cohort at baseline was not 
significantly lower than in adult pigs, reflecting that these 
young animals displayed a surprisingly mature and com-
petent complement system.
The peroxidase enzyme MPO is released upon oxida-
tive burst, is prone to cause damage to host cells and tis-
sue, and is implicated in inflammatory lung pathologies 
[19]. The combined inhibition of C5 and CD14 attenu-
ated MPO activity in the BALF by 42%. However, it is not 
possible to differentially attribute the specific effect 
achieved by inhibiting the 2 pathways, so ex vivo experi-
ments using human whole blood were performed. Indi-
vidual C5 or CD14 inhibition did not attenuate meconi-
um-induced MPO formation in human whole blood, but 
inhibition of the 2 in combination significantly attenu-
ated the formation by 64%. Similar observations have 
previously been made in bacteria-induced inflammation 
and reflect a synergistic interaction between the comple-
ment system and CD14 [24]. This phenomenon under-
scores the redundancy of host defense where one of the 
pathways substitutes the other if it is blocked. 
The study focused on the inflammatory impact of 
MAS and specifically addressed the role of the upstream 
part of the innate immune system. Complement, with 
the central C5 molecule, and the TLR system, with the 
important coreceptor CD14, were particularly addressed 
in this study. Although clinically less relevant than a de-
layed intervention, the inhibitors were provided prior to 
meconium instillation, thus minimizing an initial acti-
vation of these upstream innate immune pathways, as a 
proof of concept design. The high concentration of me-
conium used rapidly induced respiratory distress in all 
the animals and so they required extensive respiratory 
support. However, no improved lung function was ob-
served by the combined treatment regimen, and it is rea-
sonable to suggest that beneficial effects may have been 
masked by the overwhelming severity of the model. Still, 
the model induced a systemic inflammatory response in 
all animals challenged with meconium, underscoring 
the important role of inflammation in MAS. Important-
ly, the data demonstrate clearly that combined inhibi-
tion of C5 and CD14 had a pronounced attenuating ef-
fect on the systemic release of deleterious inflammatory 
mediators (particularly IL-1β), indicating inflamma-
some activation but also IL-6 and local MPO activity in 
the BALF.
These novel findings should be considered in studies 
exploring future therapeutic approaches for the treat-
ment of MAS.
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